Navigation Links
Roxane Laboratories, Inc. Announces the Launch of Risperidone Oral Solution 1mg/mL
Date:7/29/2009

COLUMBUS, Ohio, July 29 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Risperidone Oral Solution, 1mg/mL by the U.S. Food and Drug Administration. The product is available in 30mL bottles for immediate shipment to wholesalers and pharmacies nationwide.

Roxane Laboratories' Risperidone Oral Solution, 1mg/mL are AA rated to RISPERDAL(R) (risperidone) oral solution. Annual sales of Risperidone Oral Solution, 1mg/mL are approximately $69.6 Million(1).

Full prescribing information for Risperidone Oral Solution, 1mg/mL is available on the Roxane Laboratories website at www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 80 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled- release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical comp
'/>"/>

SOURCE Roxane Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
2. Roxane Laboratories, Inc. Announces the Launch of Balsalazide Disodium Capsules, 750mg
3. Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg
4. Roxane Laboratories, Inc. Announces the Launch of Acarbose Tablets
5. Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules
6. Roxane Laboratories, Inc. Announces the Approval of Morphine Sulfate Tablets and Oral Solution
7. Roxane Laboratories, Inc. Initiates a Nationwide Voluntary Recall of Two Manufacturing Lots of Sodium Polystyrene Sulfonate Suspension in the US and Puerto Rico
8. Roxane Laboratories, Inc. Announces the Launch of Levetiracetam Tablets and Oral Solution
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Long Beach, CA (PRWEB) May 21, 2013 ... the 3rd Annual EB-5 Investment Summit: Dealmakers Conference ... The Dealmakers Conference will focus on exploring alternative ... will provide the latest market, legal and economic ... executives, immigration and legal professionals within the EB-5 ...
(Date:5/21/2013)... Paris, France: The Orsiro stent, which is a ... polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting ... late lumen loss at nine months in the ... 2013 today. , The BIOFLOW-II substudy used intravascular ... quantitatively assess neointimal hyperplasia and stent apposition at ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 According to ... to Rethink the Use of Botox,” Botox injections ... since their approval in 2002 (Go to goo.gl/8iYbD). Although it ... quite popular with men. The injection makes facial wrinkles less ... Botox injection last for about three months. This means that ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 The ... on cable networks and cable channels across the country, ... on its YouTube channel. The producers of the series ... in the shipping industry, the manufacturing industry, health-related companies, ... medical facilities and medical practitioners in all parts of ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving ... residents in the Creative Corridor region, is releasing results ... news conference on Thursday, May 23rd at 10:30 a.m. ... 2008. , The survey is a critical ... efforts that attract, nurture and retain people of diverse ...
Breaking Medicine News(10 mins):Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2
... as patient engagement, physician communication, and staff coordination may ... patient survival rates than others, according to a study ... Journal of the American Society of Nephrology (CJASN). ... figure out what top-performing dialysis units might be doing ...
... will receive a $2.3 million New Innovator Award today ... platelets and the technology that makes them work. ... to build platelets of biodegradable polymers, which link with ... and fellow researchers initially pursued the technology after seeing ...
... (BMC) has been awarded a four year, $5.7 million ... (NHLBI) for investigators from Boston University School of Medicine ... Cardiovascular Outcomes and Disparities. The goal of the Center ... health reform on cardiovascular (CV) care and outcomes, and ...
... Gardner HealthDay Reporter , WEDNESDAY, Sept. 29 (HealthDay ... younger women finds that screening can lower the risk of ... The study, done in Sweden, found that women who were ... 1,250 women five times over a 10-year period would save ...
... Kang Zhang, MD, PhD, professor of ophthalmology at the ... director of UCSD,s Institute of Genomic Medicine, has been ... Zhang and co-principal investigators Sheng Ding, PhD, from ... the University of Washington, received the highest possible scores ...
... of immunotherapy to children with neuroblastoma, a nervous system ... and free of disease progression after two years, according ... School of Medicine and fellow institutions. The percentage rose ... to 66 percent for children receiving immunotherapy plus standard ...
Cached Medicine News:Health News:Why do some dialysis centers have higher survival rates? 2Health News:Researchers to study effects of Mass. health reform 2Health News:Mammograms Save Lives for Women in Their 40s, Study Says 2Health News:Mammograms Save Lives for Women in Their 40s, Study Says 3Health News:UCSD receives NIH Transformative R01 Award for stimulation of neuron regeneration in the retina 2Health News:UCSD receives NIH Transformative R01 Award for stimulation of neuron regeneration in the retina 3Health News:Addition of immunotherapy boosts pediatric cancer survival in children with neuroblastoma 2
(Date:5/21/2013)... , May 21, 2013  Cephasonics, a ... today announced the introduction of the cQuest ... network-based communications with all cQuest Ultrasound™ hardware ... technology, including this new capability, at Hospitalar ... Brazil from May 21-24.  Cephasonics ...
(Date:5/21/2013)... May 21, 2013 BioElectronics Corp. (PINKSHEETS: ... electronic devices, announced that CEO, Andrew ... the FDA,s Medical Advisory Committee, Orthopedic and Rehabilitation ... for over the counter sales. "It,s ... medical device classification schema," Whelan said.  "While the ...
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
Breaking Medicine Technology:Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... 7 NeuroVasx, Inc. announced,today the completion of a private ... of Minneapolis, MN and the Stephens Group of Little,Rock, AR. ... also announced completion of long term follow up on 20,patients ... which was completed in May. The company intends to announce ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today announced ... DX(R) breast cancer test are scheduled to be ... Symposium, taking place,December 13-16, 2007. Oncotype DX is ... the likelihood of recurrence and the likelihood,of chemotherapy ...
Cached Medicine Technology:Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 2Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: